Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A discussion on the Phase V Research report released on Linzess adverse events and poor patient experience. There will be a focus on the FAERS reported deaths & if they are more likely disease or drug related

Ticker(s): IRWD, AGN, SGYP

Who's the expert?

Name: Dr Philip Schoenfeld - MD

Institution: Detroit VA Medical Center

Bio:

  • Chief of Gastroenterology at the Detroit VA medical center and previous Director of Gastrointestinal Epidemiology and Professor of Medicine at University of Michigan
  • Co-authored the American College of Gastroenterology’s Guideline on Colon Cancer Screening and the American College of Gastroenterology/American Society for Gastrointestinal Endoscopy Position Statement on Quality Indicators in Colonoscopy
  • Has published more than 100 original research studies in peer-reviewed journals and past Associate Editor (Colon) for American Journal of Gastroenterology; has served on the editorial boards of Alimentary Pharmacology and Therapeutics and Journal of Clinical Gastroenterology

Interview Questions
Q1.

How has your experience treating patients with Linzess been? Do the points of patient issues highlighted in the Phase V Research report sound representative of your experience?

Added By: joe_mccann
Q2.

Looking at the deaths in the FAERS database, what impact does that have on your opinion of the drug?

Added By: joe_mccann
Q3.

A specific case of death following fecal vomiting was highlighted in the Phase V report.  Does this sound potentially drug related or is it a potential outcome of severe IBS-C?

Added By: joe_mccann
Q4.

Why was immunogenicity never talked about by the company? What do physicians think about this? 

Added By: katyand
Q5.

Do you think there is enough evidence at this point to suggest that Linzess is acting systemically?What would be the implications of a systemic action by Linzess?

Added By: katyand
Q6.

Have you rendered services to Ironwood (such as consulting, etc)? Have you received payment from Ironwood and if yes, in what form and for which services? Have you interacted with the company in the past week? 

Added By: katyand
Q7.

If Linzess is having severe issue in the real world, how much of a read across does this have for plecanatide? Is this a net positive or negative in your mind for plecanatide?

Added By: joe_mccann
Q8.

How much of an advantage is Plecanatide's lower diarrhea rate compared to Linzness?  Would you be more likely to prescribe Plecanatide based on fewer side effects?

Added By: biocourseinc
Q9.

What has your experience been working with Synergy compared to other companies?

Added By: biocourseinc

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.